Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Quadra Allure MP™ CRT-P Pacemaker
Clinical Evidence

More Options to Make
Non-Response a Non-Issue

The Quadra Allure MP™ CRT-P brings MultiPoint™ Pacing (MPP), an Abbott innovated technology, to cardiac resynchronization therapy pacemakers (CRT-Ps).

Overview

MultiPoint Pacing technology is designed to deliver multiple independent left ventricular (LV) pacing pulses from a single quadripolar lead to provide you with CRT options to change:

  • Pattern of depolarization
  • Engagement of areas around scar tissue
  • Hemodynamics
  • Resynchronization

Using the Quadra Allure MP CRT-P with Quartet™ quadripolar LV pacing lead, with its four pacing electrodes and 14 pacing vectors, provides more options and greater control in CRT response.
 

U.S. IDE STUDY: IMPORTANCE OF MPP™ TECHNOLOGY PROGRAMMING1

The recent IDE study1 post-hoc subanalysis (n = 199) showed that wider cathode spacing and near-simultaneous intraventricular timing delays provide best MPP technology response at 87 percent and “super-response” at 54 percent (52 patients).1

See details of the U.S. IDE study and other clinical support for MultiPoint Pacing.
 

ADDITIONAL INTERNATIONAL CLINICAL DATA

This evidence builds on our quadripolar standard of care, which has offered you more options to pace at the preferred LV site, resulting in:

  • Improved CRT outcome2,3
  • Fewer surgical revisions4
  • Reduced need for lead repositioning at implant, leading to shorter procedure times and decreased fluoroscopic exposure5,6
  • More basal pacing opportunities without compromising lead stability7,8


QUADRA ALLURE MP CRT-P ADVANCED FEATURES AND BENEFITS

Designed to Optimize Tissue Selection

The Quadra Allure MP CRT-P offers Auto VectSelect Quartet™ Test that:

  • Automatically identifies tissue sites with the latest activation via RV-LV conduction delays measurements
  • Performs threshold testing, assesses LVCap™ Confirm applicability and allows marking of PNS

Pacing at the tissue site of latest activation improves:

  • Acute hemodynamic response9
  • Reverse remodeling10
  • Quality of life10

Enhanced Programming Options
  • SyncAV™ CRT technology automatically adjusts pacing based on real-time changes in a patient's cardiac condition.

Providing Insightful Diagnostics and RF Monitoring

Quadra Allure MP CRT-P helps you better manage your patients’ heart failure with intuitive programming options and timely access to their vital heart failure diagnostic data through radio frequency (RF) monitoring, providing:

  • CorVue™ congestion monitoring for an earlier insight into HF progression
  • Daily remote monitoring of AT/AF alerts for changes in the patient’s AF condition
  • DirectTrend™ reports for a simplified look at all device data

BUILDING COMPREHENSIVE HEART FAILURE MANAGEMENT

The Quadra Allure MP™ CRT-P Is one of our heart failure management therapies. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about our approach to heart failure management.


Resources and Documentation

Product Manuals (Instructions for Use)

References

  1. Tomassoni, G., Baker II, J., Corbisiero, R., Love, C., Martin, D., Sheppard, R., Worley, S., Varma, N., & Niazi, I. (2016, May). Safety and efficacy of multipoint pacing in cardiac resynchronization therapy: The MultiPoint Pacing (MPP) IDE Study. Presented at the meeting of the Heart Rhythm Society, San Francisco, CA, LBCT 01-03.
  2. Forleo,. G. B., Mantica, M., Di Biase, L., Panattoni, G., Della Rocca, D. G., Papavasileiou, L. P., … Romeo, F. (2012). Clinical and procedural outcome of patients implanted with a quadripolar left ventricular lead: Early results of a prospective multicenter study. Heart Rhythm, 9(11), 1822-1828. https://www.heartrhythmjournal.com/article/S1547-5271(12)00767-9/fulltext
  3. Turakhia, M., Cao, M., Fischer, A., Arnold, E. M., Sloman, L. S., Dalal, N., & Gold, M. (2014, June). Reduced mortality with quadripolar compared to bipolar left ventricular leads in cardiac resynchronization therapy. Presented at the World Congress in Cardiac Electrophysiology and Cardiac Techniques, Nice, France. Retrospective analysis; not prespecified.
  4. Forleo, G. B., Della Rocca, D. G., Papavasileiou, L. P., Molfetta, A. D., Santini, L., & Romeo, F. (2011). Left ventricular pacing with a new quadripolar transvenous lead for CRT: Early results of a prospective comparison with conventional implant outcomes. Heart Rhythm, 8(1), 31-37. https://www.heartrhythmjournal.com/article/S1547-5271(10)01019-2/fulltext
  5. Dänschel, W., Sperzel, J. K., Gutleben, K., Kranig, W., Mortensen, P., Connelly, D., … Hallier, B. (2010). Initial clinical experience with a novel left ventricular quadripolar lead. Europace, 12(Suppl. 1), i127. https://academic.oup.com/europace/article/12/suppl_1/i13/492430
  6. Duray, G. Z., Hohnloser, S. H., Israel, C. W. (2008). Coronary sinus side branches for cardiac resynchronization therapy: prospective evaluation of availability, implant success, and procedural determinants. Journal of Cardiovascular Electrophysiology, 19(5), 489-494. https://onlinelibrary.wiley.com/doi/10.1111/j.1540-8167.2007.01096.x
  7. Merchant, F. M., Heist, E. K., McCarty, D., Kumar, P., Das, S., Blendea, D., … Singh, J. P. (2010). Impact of segmental left ventricular lead position on cardiac resynchronization therapy outcomes. Heart Rhythm, 7(5), 639-644. http://dx.doi.org/10.1016/j.htrhtm.2010.01.035
  8. Singh, J. P., Klein, H. U., Huang, D. T., Reek, S., Kuniss, M., Quesada, A., … Moss, A. J. (2011). Left ventricular lead position and clinical outcome in the Multicenter Automatic Defibrillator Implantation Trial Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation, 123(11), 1159-1166. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.110.000646
  9. Yu, Y., Auricchio, A., Butter, C., Stellbrink, C., Vogt, J., Goehring, A., & Spinelli, J. (2002). Assessment of resynchronization effectiveness of left ventricular lead site. Journal of Cardiac Failure, 8(4S), S72.
  10. Gold, M., Birgersdotter-Green, U., Singh J., Ellenbogen, K., Yu, Y., Meyer, T., …Tchou, P. (2011). The relationship between ventricular electrical delay and left ventricular remodeling with cardiac resynchronization therapy. European Heart Journal, 32(20), 2516-2524. https://academic.oup.com/eurheartj/article/32/20/2516/487679

MAT-2205631 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.



Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.



Do you want to continue? 

YesNo